Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments, biopharma, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance.
With some now considering the field as the new ‘Wall Street darling’, especially given the $1 billion launch of the AMR action fund, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs.
Bringing together 60+ senior leaders from large pharma, innovative biotech, academia and investment companies, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates, novel modalities and effective strategies, that address market sustainability and aim for superiority.
CARB-X participants include Kevin Outterson, Executive Director, who will be leading the session “Surviving FDA Approval of your Antibiotic” on Wednesday April 21 at 9:25am ET / 6:25am PDT. He will touch upon:
- What can we learn from the past decade of FDA antibiotic approvals? •
- Niche markets where your drug can differentiate from generics
- Non-dilutive funding: CARB-X, BARDA, HERA
- Exit: AMR Action Fund, PASTEUR
CARB-X funded companies participating include Peptilogics, Vedanta, Antabio, Bioversys, ContraFect, Locus, Techulon, Summit, and MicuRx.
More about the event here.